Reuters: Private Equity: Mylan no longer interested in Rottapharm -sources

Reuters: Private Equity Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Mylan no longer interested in Rottapharm -sources Mar 15th 2012, 17:58 By Sophie Sassard and Simon Meads March 15 | Thu Mar 15, 2012 1:58pm EDT March 15 (Reuters) - Generics drug maker Mylan has pulled out of talks to buy a stake in Italian pharma group Rottapharm, two people familiar with the situation said, posing another setback in the arduous sales process that kicked off in the middle of last year. The Rovati family had been looking to find an investor among rival pharma groups such as Mylan, Forest Laboratories and Watson Pharmaceuticals, after it failed to sell a minority stake to private equity houses. But the deal now had hit trouble again, the sources said, because the selling family could not agree to give up control of the company, and was not prepared to compromise enough on price either.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions